Tag: Therapeutic peptides

While peptides are generally associated with a lower risk of drug-drug interactions (DDIs) compared to small-molecule drugs, specific modifications and mechanisms can increase this potential, as highlighted in a 2025 review of approved peptide drugs. Therefore, the question, 'Do peptides have drug interactions?', necessitates a nuanced understanding of their pharmacology.

Globally, over 80 peptide drugs have been approved, and the market is growing rapidly [1.8.4]. Despite their high target specificity, their development faces significant hurdles [1.7.1]. So, **what is a drawback of peptides?** Key issues include poor stability, rapid degradation, and low oral bioavailability, which often necessitates administration via injection [1.4.2, 1.4.4].

With over 100 peptide drugs approved by the FDA for various medical conditions, safety is a paramount concern for both therapeutic and supplemental uses. Determining **what is the safest peptide** is a complex question, as the answer depends on the peptide's purpose, regulatory status, sourcing, and individual health factors.